13 September 2019 - - German protein drug conjugates developer Tubulis and Glycotope, a clinical-stage immuno-oncology company, have signed a research and feasibility agreement, providing Glycotope access to Tubulis' proprietary antibody drug conjugate technologies, the companies said.

Glycotope will have non-exclusive access to Tubulis' Tub-tag technology for one of its ADC candidates.

Tub-tag allows for site-specific and stable ADC conjugation by implementing biology-inspired aspects for enhanced ADC stability.

In addition, Glycotope receives the option to evaluate the potential of Tubulis' ADC screening platform P5.

Financial terms of the collaboration were not disclosed.

Tubulis generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology.

Its goal is to expand the therapeutic potential of antibody drug conjugates ushering in a new era and delivering better outcomes for patients. The company aims to advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets.

Glycotope is a clinical stage biotechnology company applying world-leading glyco-biology expertise to develop highly innovative mAb-based therapeutics in immuno-oncology and oncology. The company's Glycobodies target specific glyco-epitopes to generate first-in-class products.

The lead candidate, Gatipotozumab, targets TA-MUC1 and is in the clinic for the treatment of solid tumors in combination with an anti-EGRF antibody.

It is also being developed in an ADC format under a worldwide licensing agreement with Daiichi Sankyo and as a bispecific IL-15 and CD-3. Glycotope's technology provides a platform for the development of additional clinical and pre-clinical programmes with an array of modes of action providing a unique offering in the immuno-oncology and oncology space.